OpenLB
Open Library of Bioscience
Advanced Search
Journal of controlled release : official journal of the Controlled Release Society
12 28, 2018;292 256-276.

Biomaterials for vaccine-based cancer immunotherapy.

Rui Zhang, Margaret M Billingsley, Michael J Mitchell
Author Information
  1. Rui Zhang: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States.
  2. Margaret M Billingsley: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States.
  3. Michael J Mitchell: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States. Electronic address: mjmitch@seas.upenn.edu.
PMID: 30312721 DOI: 10.1016/j.jconrel.2018.10.008

Abstract

The development of therapeutic cancer vaccines as a means to generate immune reactivity against tumors has been explored since the early discovery of tumor-specific antigens by Georg Klein in the 1960s. However, challenges including weak immunogenicity, systemic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. Advances in the design and implementation of biomaterials are now enabling enhanced efficacy and reduced toxicity of cancer vaccines by controlling the presentation and release of vaccine components to immune cells and their microenvironment. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (including DNA, mRNA, peptide/protein, and cell-based vaccines) along with novel biomaterial-based delivery technologies that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered.

Keywords

Biomaterials Cancer vaccine Immunotherapy Nanomedicine Nucleic acid delivery Personalized therapy Targeted delivery Translational research

References

  1. Peptides. 2017 Jan;87:50-63 [PMID: 27887988]
  2. Immunotherapy. 2009 Jul;1(4):513-6 [PMID: 20635981]
  3. Nature. 1992 Mar 12;356(6365):152-4 [PMID: 1545867]
  4. Adv Mater. 2017 Aug;29(29): [PMID: 28556553]
  5. Adv Mater. 2012 Jul 24;24(28):3845-9 [PMID: 22550019]
  6. Immunity. 2005 Aug;23(2):165-75 [PMID: 16111635]
  7. Acta Biomater. 2017 Mar 1;50:417-427 [PMID: 28063991]
  8. J Clin Invest. 2015 Sep;125(9):3401-12 [PMID: 26214521]
  9. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6 [PMID: 18650390]
  10. J Control Release. 2017 Nov 28;266:109-118 [PMID: 28943194]
  11. J Vis Exp. 2014 Jan 02;(83):e50984 [PMID: 24430972]
  12. Nat Commun. 2018 Apr 18;9(1):1532 [PMID: 29670088]
  13. Nano Lett. 2017 May 10;17(5):2879-2886 [PMID: 28287740]
  14. Clin Cancer Res. 2009 Jan 1;15(1):361-7 [PMID: 19118066]
  15. ACS Nano. 2014 Jun 24;8(6):5696-706 [PMID: 24821383]
  16. Nat Rev Immunol. 2018 Mar;18(3):168-182 [PMID: 29226910]
  17. J Immunother Cancer. 2015 Apr 21;3:14 [PMID: 25901286]
  18. Biomacromolecules. 2014 Oct 13;15(10):3836-45 [PMID: 25207465]
  19. Mol Ther. 2008 Nov;16(11):1833-40 [PMID: 18797453]
  20. Biomaterials. 2018 Sep;178:728-737 [PMID: 29428163]
  21. J Control Release. 2017 Apr 10;251:92-100 [PMID: 28257987]
  22. Science. 2018 Mar 23;359(6382):1355-1360 [PMID: 29567706]
  23. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6147-E6156 [PMID: 28696296]
  24. Vaccine. 2006 Mar 15;24(12):2065-70 [PMID: 16337719]
  25. Science. 2015 Nov 20;350(6263):972-8 [PMID: 26516201]
  26. Gene Ther. 2017 Jul;24(7):408-415 [PMID: 28492521]
  27. FASEB J. 1996 Oct;10(12):1378-87 [PMID: 8903508]
  28. Nat Rev Genet. 2008 Oct;9(10):776-88 [PMID: 18781156]
  29. Pediatr Blood Cancer. 2010 Apr;54(4):519-25 [PMID: 19852061]
  30. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9 [PMID: 22908294]
  31. Cancer Immunol Res. 2015 Aug;3(8):836-43 [PMID: 26156157]
  32. AAPS J. 2018 Jun 1;20(4):73 [PMID: 29858738]
  33. Immunol Cell Biol. 2011 Mar;89(3):332-9 [PMID: 21301476]
  34. J Med Chem. 2011 Dec 8;54(23):8148-60 [PMID: 22007676]
  35. Eur J Cell Biol. 2004 Apr;83(3):97-111 [PMID: 15202568]
  36. J Control Release. 2015 Feb 28;200:1-12 [PMID: 25540903]
  37. Adv Immunol. 2016;130:191-249 [PMID: 26923002]
  38. Pharm Res. 2016 Oct;33(10):2373-87 [PMID: 27299311]
  39. Emerg Infect Dis. 2017 May;23(5):773-781 [PMID: 28418292]
  40. J Natl Cancer Inst. 1984 Apr;72(4):955-62 [PMID: 6200641]
  41. J Exp Clin Cancer Res. 2016 Oct 26;35(1):168 [PMID: 27782834]
  42. Blood. 2012 Sep 6;120(10):2011-20 [PMID: 22791285]
  43. Mol Immunol. 2018 Jun;98:13-18 [PMID: 29525074]
  44. Nat Med. 2003 Jan;9(1):33-9 [PMID: 12496961]
  45. Front Physiol. 2012 May 22;3:138 [PMID: 22661952]
  46. Eur J Immunol. 2001 Jun;31(6):1780-9 [PMID: 11385623]
  47. Nat Med. 2004 May;10(5):475-80 [PMID: 15122249]
  48. Proc Natl Acad Sci U S A. 2013 Dec 3;110(49):19902-7 [PMID: 24248387]
  49. Clin Res Cardiol. 2011 Sep;100(9):737-44 [PMID: 21416191]
  50. J Immunother. 2017 Jan;40(1):11-20 [PMID: 27681378]
  51. Curr Opin Immunol. 2011 Jun;23(3):421-9 [PMID: 21530212]
  52. Nat Biotechnol. 2014 Apr;32(4):364-72 [PMID: 24633240]
  53. Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6 [PMID: 25568796]
  54. Nat Rev Immunol. 2012 Jul 13;12(8):557-69 [PMID: 22790179]
  55. Am J Vet Res. 2011 Dec;72(12):1631-8 [PMID: 22126691]
  56. J Infect Dis. 2015 Mar 15;211(6):947-55 [PMID: 25234719]
  57. Nature. 2004 Jan 8;427(6970):154-9 [PMID: 14712275]
  58. Annu Rev Immunol. 2002;20:621-67 [PMID: 11861614]
  59. Sci Rep. 2017 Mar 21;7(1):252 [PMID: 28325910]
  60. FASEB J. 2012 Mar;26(3):1272-9 [PMID: 22106367]
  61. Clin Cancer Res. 2016 Jun 15;22(12):3025-36 [PMID: 27306793]
  62. Int J Pharm. 2007 Jun 29;338(1-2):317-26 [PMID: 17368984]
  63. Nat Rev Cancer. 2012 Mar 22;12(4):265-77 [PMID: 22437871]
  64. J Immunol. 2012 Feb 15;188(4):1592-9 [PMID: 22231700]
  65. Cancer Prev Res (Phila). 2013 Jan;6(1):18-26 [PMID: 23248097]
  66. Curr Opin Immunol. 2017 Aug;47:44-51 [PMID: 28734174]
  67. Nat Rev Drug Discov. 2007 Apr;6(4):287-93 [PMID: 17380152]
  68. Am J Kidney Dis. 2000 Nov;36(5):976-82 [PMID: 11054354]
  69. Science. 2007 Jan 5;315(5808):107-11 [PMID: 17204652]
  70. Nat Biotechnol. 2002 Jan;20(1):64-9 [PMID: 11753364]
  71. Nat Mater. 2018 Sep;17(9):761-772 [PMID: 30104668]
  72. Trends Cell Biol. 2014 Jun;24(6):360-9 [PMID: 24439965]
  73. ACS Nano. 2015 Jun 23;9(6):6465-77 [PMID: 26035231]
  74. Int J Cancer. 2001 Nov;94(4):531-9 [PMID: 11745440]
  75. Int J Pharm. 2017 Jan 10;516(1-2):392-400 [PMID: 27884715]
  76. J Control Release. 2009 Sep 15;138(3):214-23 [PMID: 19376167]
  77. Sci Transl Med. 2009 Nov 25;1(8):8ra19 [PMID: 20368186]
  78. ACS Appl Mater Interfaces. 2016 Jul 27;8(29):18722-31 [PMID: 27380137]
  79. Biomaterials. 2016 Apr;85:232-45 [PMID: 26874285]
  80. Mol Ther. 2018 Feb 7;26(2):420-434 [PMID: 29249397]
  81. PLoS One. 2013 Apr 23;8(4):e61646 [PMID: 23626707]
  82. Int J Nanomedicine. 2014 Nov 12;9:5231-46 [PMID: 25419128]
  83. Adv Drug Deliv Rev. 2013 Jan;65(1):100-3 [PMID: 22960787]
  84. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1428-33 [PMID: 23297227]
  85. FASEB J. 2013 Aug;27(8):3272-83 [PMID: 23671272]
  86. Nat Rev Immunol. 2011 Nov 11;11(12):823-36 [PMID: 22076556]
  87. Nat Rev Cancer. 2006 Jun;6(6):449-58 [PMID: 16723991]
  88. Cancer Res. 2013 Mar 1;73(5):1547-58 [PMID: 23436794]
  89. J Control Release. 2013 Jun 10;168(2):179-99 [PMID: 23524187]
  90. Expert Opin Biol Ther. 2008 Nov;8(11):1645-57 [PMID: 18847301]
  91. Cell Mol Immunol. 2018 Apr;15(4):346-352 [PMID: 29563613]
  92. Adv Drug Deliv Rev. 2005 Jan 10;57(3):391-410 [PMID: 15560948]
  93. Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51 [PMID: 12204596]
  94. Nat Rev Cancer. 2017 Nov;17(11):659-675 [PMID: 29026204]
  95. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3270-5 [PMID: 23401509]
  96. Immunol Rev. 2004 Jun;199:9-26 [PMID: 15233723]
  97. Nat Rev Mater. 2016;1: [PMID: 29214058]
  98. J Immunother. 2011 Jan;34(1):1-15 [PMID: 21150709]
  99. Oncotarget. 2016 Jun 28;7(26):40437-40450 [PMID: 27250027]
  100. J Control Release. 2015 May 28;206:220-31 [PMID: 25819159]
  101. AAPS J. 2013 Jan;15(1):85-94 [PMID: 23054976]
  102. Cancer J. 2011 Sep-Oct;17(5):343-50 [PMID: 21952285]
  103. Int J Pharm Investig. 2015 Jul-Sep;5(3):124-33 [PMID: 26258053]
  104. Biomaterials. 2017 Apr;122:105-113 [PMID: 28110170]
  105. Cell. 2017 Mar 9;168(6):1114-1125.e10 [PMID: 28222903]
  106. J Am Chem Soc. 2016 Jan 27;138(3):704-17 [PMID: 26741786]
  107. Vaccine. 2000 Jul 15;18(27):3134-40 [PMID: 10856793]
  108. Vaccine. 2017 Jan 5;35(2):361-368 [PMID: 27939014]
  109. Mol Ther. 2018 Feb 7;26(2):446-455 [PMID: 29275847]
  110. Cancer Immunol Immunother. 2008 Oct;57(10):1569-77 [PMID: 18523771]
  111. Peptides. 2010 Jan;31(1):184-93 [PMID: 19819278]
  112. Chembiochem. 2009 Sep 21;10(14):2311-5 [PMID: 19681087]
  113. Int J Pharm. 2008 Dec 8;364(2):298-327 [PMID: 18621492]
  114. Nature. 2016 Jun 01;534(7607):396-401 [PMID: 27281205]
  115. J Control Release. 2014 Oct 10;191:24-33 [PMID: 24698946]
  116. Vaccine. 2005 May 16;23(26):3453-68 [PMID: 15837369]
  117. Biomaterials. 2018 Nov;182:82-91 [PMID: 30107272]
  118. Vaccine. 2009 Mar 10;27(11):1764-70 [PMID: 19185050]
  119. Nanoscale. 2014 Mar 7;6(5):2782-92 [PMID: 24463404]
  120. Bioconjug Chem. 2002 Sep-Oct;13(5):966-74 [PMID: 12236778]
  121. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4133-42 [PMID: 27382155]
  122. Trends Biotechnol. 2015 Sep;33(9):514-524 [PMID: 26277289]
  123. Nat Rev Drug Discov. 2015 Nov;14(11):781-803 [PMID: 26471369]
  124. J Control Release. 2014 Oct 28;192:209-18 [PMID: 25068703]
  125. Immunity. 2018 Mar 20;48(3):434-452 [PMID: 29562194]
  126. Am J Transl Res. 2014 Jan 15;6(2):114-8 [PMID: 24489990]
  127. Vaccine. 2003 Sep 8;21(25-26):4036-42 [PMID: 12922140]
  128. Plast Reconstr Surg. 1999 Sep;104(4):1014-22 [PMID: 10654741]
  129. Cancer Immunol Immunother. 2010 Sep;59(9):1295-312 [PMID: 20532501]
  130. Biomater Sci. 2018 Jun 25;6(7):1717-1722 [PMID: 29896593]
  131. Biomaterials. 2017 May;125:81-89 [PMID: 28231510]
  132. PLoS One. 2011;6(12):e28732 [PMID: 22194898]
  133. AAPS J. 2015 Jan;17(1):216-26 [PMID: 25387996]
  134. Adv Mater Interfaces. 2015 Jan 7;2(1): [PMID: 26167449]
  135. Nanomedicine. 2018 Feb;14(2):237-246 [PMID: 29127039]
  136. Biomacromolecules. 2007 Apr;8(4):1093-100 [PMID: 17326678]
  137. Sci Transl Med. 2018 Feb 21;10(429): [PMID: 29467299]
  138. Curr Opin Immunol. 2014 Apr;27:26-32 [PMID: 24513968]
  139. Cancer Res. 2013 Aug 1;73(15):4629-40 [PMID: 23722543]
  140. Biomaterials. 2016 Mar;83:249-56 [PMID: 26784009]
  141. Molecules. 2017 Dec 07;22(12): [PMID: 29215573]
  142. Lancet Oncol. 2014 Jun;15(7):e257-67 [PMID: 24872109]
  143. J Immunol. 2008 Sep 15;181(6):3755-9 [PMID: 18768827]
  144. Biomaterials. 2014 Jan;35(1):269-277 [PMID: 24099710]
  145. Pharmaceutics. 2017 Mar 27;9(2): [PMID: 28346375]
  146. Bioconjug Chem. 2017 Jul 19;28(7):1993-2000 [PMID: 28644608]
  147. Biomater Sci. 2017 Jan 31;5(2):223-233 [PMID: 27918020]
  148. ACS Nano. 2017 Mar 28;11(3):2531-2544 [PMID: 28157292]
  149. Daru. 2013 Jul 17;21(1):58 [PMID: 23866721]
  150. Cancer Res. 2017 Jan 15;77(2):312-319 [PMID: 27872096]
  151. Front Immunol. 2013 Jan 10;3:406 [PMID: 23335921]
  152. Nanomedicine. 2006 Mar;2(1):8-21 [PMID: 17292111]
  153. Science. 2010 Feb 5;327(5966):656-61 [PMID: 20133564]
  154. Nat Rev Drug Discov. 2014 Oct;13(10):759-80 [PMID: 25233993]
  155. Biotechnol Law Rep. 2015 Feb 1;34(1):15-37 [PMID: 25713472]
  156. J Control Release. 2006 Jul 20;113(3):261-70 [PMID: 16793161]
  157. Clin Cancer Res. 2012 Oct 15;18(20):5628-38 [PMID: 22904105]
  158. J Exp Med. 2000 Dec 18;192(12):1685-96 [PMID: 11120766]
  159. Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59 [PMID: 15350294]
  160. Cancer Immunol Res. 2014 May;2(5):436-47 [PMID: 24795356]
  161. J Immunol. 1997 Apr 15;158(8):3635-9 [PMID: 9103425]
  162. Adv Healthc Mater. 2016 Jun;5(12):1413-9 [PMID: 27100566]
  163. Nat Mater. 2013 Nov;12(11):978-90 [PMID: 24150416]
  164. Nat Methods. 2016 Oct;13(10):868-74 [PMID: 27595405]
  165. Nat Rev Cancer. 2016 Jan;16(1):56-66 [PMID: 26694936]
  166. J Control Release. 2010 Dec 1;148(2):135-46 [PMID: 20797419]
  167. Cancer Res. 2017 Jan 15;77(2):238-246 [PMID: 27815391]
  168. Vaccine. 2002 Jul 26;20(23-24):2857-65 [PMID: 12126895]
  169. Biomaterials. 2016 Apr;86:83-91 [PMID: 26894870]
  170. Bioconjug Chem. 2010 Jan;21(1):39-45 [PMID: 20020767]
  171. Nature. 2014 Mar 27;507(7493):519-22 [PMID: 24531764]
  172. Immunity. 2013 Jul 25;39(1):38-48 [PMID: 23890062]
  173. BMC Bioinformatics. 2018 May 23;19(1):180 [PMID: 29792160]
  174. Hum Vaccin Immunother. 2015;11(5):1184-91 [PMID: 25868476]
  175. Adv Mater. 2017 Aug;29(31): [PMID: 28620970]
  176. PLoS One. 2016 Aug 15;11(8):e0161193 [PMID: 27525409]
  177. Sci Rep. 2018 Aug 21;8(1):12519 [PMID: 30131591]
  178. Curr Opin Immunol. 2014 Apr;27:16-25 [PMID: 24531241]
  179. Hum Vaccin Immunother. 2014;10(11):3153-64 [PMID: 25625927]
  180. J Hepatol. 2015 Feb;62(2):458-68 [PMID: 25315649]
  181. Trends Immunol. 2009 Jan;30(1):23-32 [PMID: 19059004]
  182. Nat Biotechnol. 2007 Oct;25(10):1159-64 [PMID: 17873867]
  183. J Control Release. 2017 Jun 28;256:56-67 [PMID: 28428066]
  184. Vaccine. 2018 Jan 25;36(4):438-441 [PMID: 29248267]
  185. Nat Nanotechnol. 2007 Apr;2(4):249-55 [PMID: 18654271]
  186. Phys Biol. 2018 Oct 22;15(6):065006 [PMID: 30124431]
  187. Nat Rev Immunol. 2005 Aug;5(8):617-28 [PMID: 16056255]
  188. Nat Rev Genet. 2016 May 17;17(6):333-51 [PMID: 27184599]
  189. Vaccine. 2008 Sep 15;26(39):5046-57 [PMID: 18680779]
  190. Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600 [PMID: 29240946]
  191. Cancer Res. 2014 Mar 15;74(6):1670-81 [PMID: 24480625]
  192. Nat Commun. 2015 Aug 12;6:7556 [PMID: 26265369]
  193. Macromol Rapid Commun. 2017 Oct;38(20): [PMID: 28895249]
  194. Angew Chem Int Ed Engl. 2016 Jan 26;55(5):1899-903 [PMID: 26404897]
  195. Adv Drug Deliv Rev. 2017 Feb;110-111:80-101 [PMID: 27539561]
  196. Adv Mater. 2012 Jul 24;24(28):3757-78 [PMID: 22528985]
  197. Nat Commun. 2018 Jan 2;9(1):6 [PMID: 29295974]
  198. Sci Rep. 2016 Apr 14;6:24506 [PMID: 27074905]
  199. BioDrugs. 2015 Oct;29(5):301-7 [PMID: 26403092]
  200. Blood. 2018 Jan 4;131(1):58-67 [PMID: 29118008]
  201. Expert Rev Vaccines. 2014 Mar;13(3):399-415 [PMID: 24512188]
  202. Nucleic Acids Res. 2011 Nov;39(21):e142 [PMID: 21890902]
  203. Adv Cancer Res. 2013;119:421-75 [PMID: 23870514]
  204. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1864-9 [PMID: 20080679]
  205. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19590-5 [PMID: 23150549]
  206. Eur J Immunol. 2005 Dec;35(12):3591-8 [PMID: 16285011]
  207. J Control Release. 2015 Nov 10;217:345-51 [PMID: 26264835]
  208. J Control Release. 2017 Nov 28;266:27-35 [PMID: 28917531]
  209. Nat Mater. 2018 Jun;17(6):528-534 [PMID: 29507416]
  210. Nanomedicine (Lond). 2014 Jan;9(1):121-34 [PMID: 24354814]
  211. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1506 [PMID: 29333729]
  212. Cell Rep. 2012 Mar 29;1(3):191-9 [PMID: 22832193]
  213. Oncotarget. 2015 Jun 30;6(18):15772-87 [PMID: 26158218]
  214. Bioconjug Chem. 2018 Mar 21;29(3):776-785 [PMID: 29436221]
  215. J Clin Oncol. 2002 Apr 15;20(8):2058-66 [PMID: 11956266]
  216. Vaccine. 2017 Feb 15;35(7):1094-1100 [PMID: 27449681]
  217. J Control Release. 2016 Mar 10;225:230-9 [PMID: 26826307]
  218. Clin Exp Immunol. 2004 May;136(2):312-9 [PMID: 15086396]
  219. Vaccine. 2012 Nov 26;30(50):7292-9 [PMID: 23022399]
  220. ACS Macro Lett. 2017 Nov 21;6(11):1320-1324 [PMID: 35650790]
  221. Cancer. 2003 Jul 1;98(1):144-54 [PMID: 12833467]
  222. Biophys J. 2000 Dec;79(6):3153-63 [PMID: 11106620]
  223. Curr Opin Immunol. 2005 Aug;17(4):359-65 [PMID: 15955682]
  224. Nucleic Acid Ther. 2018 Feb;28(1):23-33 [PMID: 29341839]
  225. Eur J Immunol. 2005 Feb;35(2):568-74 [PMID: 15682446]
  226. Semin Immunol. 2011 Feb;23(1):12-20 [PMID: 21269839]
  227. Cell. 2015 Apr 9;161(2):201-4 [PMID: 25860604]
  228. Clin Orthop Relat Res. 1991 Jan;(262):3-11 [PMID: 1984929]
  229. Curr Opin Immunol. 2014 Jun;28:1-5 [PMID: 24463269]
  230. Nature. 2011 Feb 24;470(7335):543-7 [PMID: 21350488]
  231. J Intern Med. 2003 Apr;253(4):402-10 [PMID: 12653868]
  232. Science. 1993 Mar 19;259(5102):1745-9 [PMID: 8456302]
  233. Nat Rev Drug Discov. 2018 Apr;17(4):261-279 [PMID: 29326426]
  234. Anticancer Res. 2000 Jul-Aug;20(4):2665-76 [PMID: 10953341]
  235. Bioorg Med Chem Lett. 2018 Sep 15;28(17):2850-2855 [PMID: 30076049]
  236. J Immunother. 2014 Jan;37(1):1-7 [PMID: 24316550]
  237. PLoS One. 2010 Sep 02;5(9): [PMID: 20824059]
  238. Nat Mater. 2009 Feb;8(2):151-8 [PMID: 19136947]
  239. J Immunother Cancer. 2015 Jun 16;3:26 [PMID: 26082837]
  240. Clin Cancer Res. 2011 May 15;17(10):3408-19 [PMID: 21300761]
  241. Immunity. 2009 Dec 18;31(6):873-84 [PMID: 19931471]
  242. Semin Immunol. 2010 Jun;22(3):132-43 [PMID: 20356763]
  243. Pharmacol Ther. 2017 Jun;174:27-42 [PMID: 28185916]
  244. Hum Vaccin Immunother. 2016;12(1):159-69 [PMID: 26378866]
  245. J Am Chem Soc. 2018 Jan 31;140(4):1227-1230 [PMID: 29356509]
  246. J Drug Target. 2015;23(7-8):690-7 [PMID: 26453164]
  247. Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12046-51 [PMID: 26371311]
  248. ACS Biomater Sci Eng. 2018 Jul 9;4(7):2330-2339 [PMID: 33435099]
  249. APMIS. 2003 Jul-Aug;111(7-8):675-97 [PMID: 12974772]
  250. Curr Gene Ther. 2011 Dec;11(6):479-84 [PMID: 22023477]
  251. Biomaterials. 2011 Aug;32(22):5134-47 [PMID: 21514665]
  252. J Biomed Mater Res. 1998 Dec 5;42(3):396-402 [PMID: 9788501]
  253. Clin Transl Immunology. 2016 Mar 18;5(3):e66 [PMID: 27217957]
  254. Vaccines (Basel). 2014 Jul 02;2(3):515-36 [PMID: 26344743]
  255. Eur J Pharm Biopharm. 2008 Jan;68(1):34-45 [PMID: 17881200]
  256. Nano Lett. 2017 Mar 8;17(3):1326-1335 [PMID: 28273716]
  257. Mol Ther. 2012 Mar;20(3):679-86 [PMID: 22186789]
  258. Nanoscale. 2018 May 17;10(19):9311-9319 [PMID: 29737353]
  259. Nano Lett. 2014;14(4):2181-8 [PMID: 24673373]
  260. Immunity. 2016 Feb 16;44(2):343-54 [PMID: 26872698]
  261. ACS Nano. 2015 Jul 28;9(7):6655-74 [PMID: 26149184]
  262. ACS Nano. 2018 Jun 26;12(6):5121-5129 [PMID: 29771487]
  263. Bioconjug Chem. 2018 Mar 21;29(3):733-741 [PMID: 29318872]
  264. Pharmacol Ther. 2014 Feb;141(2):222-33 [PMID: 24140083]
  265. Ann Oncol. 2006 Apr;17(4):563-70 [PMID: 16418308]
  266. Oncoimmunology. 2012 Oct 1;1(7):1111-1134 [PMID: 23170259]
  267. Nature. 2017 Mar 9;543(7644):248-251 [PMID: 28151488]
  268. Clin Cancer Res. 2015 Sep 1;21(17):3879-87 [PMID: 25967144]
  269. Cancer Immunol Immunother. 2013 Apr;62(4):639-52 [PMID: 23143746]
  270. Nucleic Acids Res. 2001 Sep 15;29(18):3882-91 [PMID: 11557821]
  271. J Dtsch Dermatol Ges. 2015 Dec;13(12):1223-35; quiz 1236-7 [PMID: 26612791]
  272. Pharmacol Ther. 2016 Sep;165:32-49 [PMID: 27235391]
  273. ACS Nano. 2014 Nov 25;8(11):11243-53 [PMID: 25318048]
  274. Nat Biotechnol. 2009 Feb;27(2):129-39 [PMID: 19204689]
  275. J Control Release. 2015 Apr 10;203:16-22 [PMID: 25660830]
  276. Mol Ther. 2016 Nov;24(11):2012-2020 [PMID: 27506450]
  277. World J Gastroenterol. 2014 Aug 14;20(30):10383-94 [PMID: 25132754]
  278. Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7240-E7249 [PMID: 27799536]
  279. Science. 2015 Apr 3;348(6230):69-74 [PMID: 25838375]
  280. Anal Chem. 2016 Feb 16;88(4):2466-71 [PMID: 26810843]
  281. Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5461-6 [PMID: 25922518]
  282. Hum Vaccin Immunother. 2015;11(8):1889-900 [PMID: 25984993]
  283. BMC Neurol. 2017 Sep 11;17(1):181 [PMID: 28893208]
  284. Immunol Cell Biol. 2004 Oct;82(5):488-96 [PMID: 15479434]
  285. Cancer Res. 2002 Oct 15;62(20):5845-52 [PMID: 12384547]
  286. Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13 [PMID: 26607445]
  287. Stem Cell Res Ther. 2015 Nov 23;6:225 [PMID: 26597928]
  288. Expert Rev Clin Immunol. 2015 Feb;11(2):213-32 [PMID: 25467734]
  289. J Control Release. 2018 Jul 28;282:131-139 [PMID: 29702142]
  290. Nature. 2015 Apr 30;520(7549):692-6 [PMID: 25901682]
  291. Nucleic Acid Ther. 2015 Apr;25(2):95-102 [PMID: 25692533]
  292. J Biomed Biotechnol. 2010;2010:174378 [PMID: 20368780]
  293. Nano Today. 2015 Aug 1;10(4):511-531 [PMID: 26640511]
  294. Immunity. 2010 Oct 29;33(4):492-503 [PMID: 21029960]
  295. Immunity. 2013 Jul 25;39(1):1-10 [PMID: 23890059]
  296. Virol J. 2016 Aug 26;13(1):143 [PMID: 27562235]
  297. Expert Rev Vaccines. 2014 Jan;13(1):9-15 [PMID: 24219096]
  298. Biotechnol Bioeng. 2018 Apr;115(4):1086-1095 [PMID: 29280498]
  299. Nat Med. 2013 Dec;19(12):1597-608 [PMID: 24309663]
  300. Biophys J. 2010 Sep 8;99(5):1342-9 [PMID: 20816045]
  301. J Control Release. 2010 Mar 3;142(2):221-8 [PMID: 19887092]
  302. Adv Mater. 2016 Oct;28(40):8912-8920 [PMID: 27558441]
  303. AAPS J. 2015 Jan;17(1):184-93 [PMID: 25331103]
  304. Nat Mater. 2017 Apr;16(4):489-496 [PMID: 28024156]
  305. ACS Biomater Sci Eng. 2015 Dec 14;1(12):1200-1205 [PMID: 26689147]
  306. Nano Lett. 2012 Oct 10;12(10):5304-10 [PMID: 22920324]
  307. Biomaterials. 2017 Nov;146:136-145 [PMID: 28918263]
  308. J Clin Invest. 2014 Mar;124(3):943-52 [PMID: 24590280]
  309. Biomacromolecules. 2014 Jun 9;15(6):1955-69 [PMID: 24798476]
  310. J Control Release. 2009 Oct 1;139(1):73-80 [PMID: 19508880]
  311. Adv Mater. 2017 Dec;29(47): [PMID: 29239517]
  312. Adv Mater. 2011 Mar 25;23(12):H41-56 [PMID: 21394792]
  313. Braz J Med Biol Res. 2012 Dec;45(12):1102-11 [PMID: 22948379]
  314. Cytobios. 1983;37(145):21-6 [PMID: 6851664]
  315. Immunol Res. 2014 Aug;59(1-3):220-8 [PMID: 24838147]
  316. Sci Rep. 2017 Jan 16;7:40312 [PMID: 28091576]
  317. Adv Mater. 2012 Mar 22;24(12):1504-34 [PMID: 22378538]
  318. ACS Biomater Sci Eng. 2018 Jul 9;4(7):2463-2472 [PMID: 33435110]
  319. Hum Vaccin Immunother. 2014;10(1):52-63 [PMID: 24064957]
  320. Int Immunol. 2014 Oct;26(10):531-8 [PMID: 24844701]
  321. Chem Rev. 2015 Oct 14;115(19):11109-46 [PMID: 26154342]
  322. Nat Commun. 2016 Oct 21;7:13193 [PMID: 27767031]
  323. Curr Opin Biotechnol. 2016 Aug;40:1-8 [PMID: 26896596]
  324. BMC Cancer. 2014 Oct 06;14:748 [PMID: 25288198]
  325. Nat Rev Immunol. 2010 Nov;10(11):787-96 [PMID: 20948547]
  326. Biomaterials. 2017 Jan;113:191-202 [PMID: 27816821]
  327. Lancet Oncol. 2014 Apr;15(4):e178-83 [PMID: 24694641]
  328. Vaccine. 2012 Feb 27;30(10):1759-66 [PMID: 22265860]
  329. Leukemia. 2007 Sep;21(9):1859-74 [PMID: 17611570]
  330. Int J Pharm. 2011 Nov 28;420(2):304-12 [PMID: 21945185]
  331. Bioorg Med Chem. 2014 Nov 15;22(22):6401-8 [PMID: 25438764]
  332. Vaccine. 2014 May 19;32(24):2882-95 [PMID: 24593999]
  333. Immune Netw. 2013 Oct;13(5):177-83 [PMID: 24198742]
  334. Biomaterials. 2015 Feb;40:88-97 [PMID: 25465442]
  335. Benef Microbes. 2017 May 30;8(3):379-391 [PMID: 28504575]
  336. Vaccine. 2017 Mar 14;35(12):1622-1629 [PMID: 28222998]
  337. Methods Mol Biol. 2014;1139:479-503 [PMID: 24619701]
  338. Ann Surg. 1974 Oct;180(4):635-43 [PMID: 4412271]
  339. Nat Biotechnol. 2015 Jan;33(1):64-72 [PMID: 25485616]
  340. Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2060-2065 [PMID: 28167778]
  341. J Control Release. 2015 Dec 10;219:610-621 [PMID: 26489733]
  342. Bioconjug Chem. 2018 Mar 21;29(3):742-747 [PMID: 29350913]
  343. Vaccine. 2013 Aug 20;31(37):3979-86 [PMID: 23770306]
  344. ACS Nano. 2018 Feb 27;12(2):912-931 [PMID: 29378114]
  345. Nano Lett. 2017 Dec 13;17(12):7387-7393 [PMID: 29144754]
  346. Nanoscale. 2017 Nov 30;9(46):18223-18228 [PMID: 29164226]
  347. Adv Healthc Mater. 2018 Mar;7(5): [PMID: 29115746]
  348. Nat Immunol. 2013 Oct;14(10):1014-22 [PMID: 24048123]
  349. Sci Rep. 2016 Oct 13;6:35323 [PMID: 27734935]
  350. Adv Drug Deliv Rev. 2014 Jul;74:28-34 [PMID: 24862579]
  351. Acta Biomater. 2018 Jan;65:36-43 [PMID: 29128539]
  352. Clin Cancer Res. 2011 Jun 1;17(11):3520-6 [PMID: 21471425]
  353. Tissue Eng Part B Rev. 2008 Jun;14(2):149-65 [PMID: 18498217]
  354. Heliyon. 2017 Jan 06;3(1):e00225 [PMID: 28194450]
  355. Methods Mol Biol. 2015;1317:17-37 [PMID: 26072399]
  356. Cell Rep. 2018 Feb 6;22(6):1484-1495 [PMID: 29425504]
  357. Cancer Cell. 2014 Jun 16;25(6):846-59 [PMID: 24898549]
  358. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-401 [PMID: 16740763]
  359. Chem Res Toxicol. 2012 Aug 20;25(8):1609-15 [PMID: 22621314]
  360. Annu Rev Biomed Eng. 2012;14:1-16 [PMID: 22524388]
  361. Nano Lett. 2012 Jul 11;12(7):3369-77 [PMID: 22650417]
  362. Hum Gene Ther. 1999 Nov 1;10(16):2719-24 [PMID: 10566900]
  363. Blood. 2013 Apr 11;121(15):2836-44 [PMID: 23390195]
  364. Mol Cancer. 2011 Jan 07;10:3 [PMID: 21211062]
  365. Adv Healthc Mater. 2018 May;7(10):e1701469 [PMID: 29441705]
  366. Ther Adv Vaccines. 2014 Nov;2(6):159-82 [PMID: 25364509]
  367. J Control Release. 2017 Dec 10;267:47-56 [PMID: 28818619]
  368. Front Immunol. 2018 Jul 02;9:1499 [PMID: 30013560]
  369. Adv Mater. 2014 Oct;26(38):6530-41 [PMID: 25155610]
  370. Theranostics. 2017 Jun 25;7(10):2575-2592 [PMID: 28819448]
  371. P T. 2017 Dec;42(12):742-755 [PMID: 29234213]
  372. Biomaterials. 2016 Aug;98:171-83 [PMID: 27192420]
  373. Vaccines (Basel). 2015 Apr 23;3(2):344-72 [PMID: 26343191]
  374. J Control Release. 2013 Nov 28;172(1):38-47 [PMID: 23933235]
  375. Nano Lett. 2018 Jun 13;18(6):3814-3822 [PMID: 29694050]
  376. Mol Ther. 2013 Jan;21(1):251-9 [PMID: 23011030]
  377. Mol Pharm. 2017 Aug 7;14(8):2815-2823 [PMID: 28686452]
  378. AAPS J. 2016 Nov;18(6):1351-1353 [PMID: 27520380]
  379. Angew Chem Int Ed Engl. 2016 Jan 22;55(4):1334-9 [PMID: 26666207]
  380. AAPS J. 2015 Mar;17(2):323-38 [PMID: 25533221]
  381. ACS Nano. 2017 May 23;11(5):4463-4474 [PMID: 28362496]
  382. Bioconjug Chem. 2018 Mar 21;29(3):771-775 [PMID: 29485848]
  383. ACS Appl Mater Interfaces. 2018 Jun 20;10(24):20315-20325 [PMID: 29808993]
  384. Expert Rev Vaccines. 2010 Jun;9(6):617-29 [PMID: 20518717]
  385. Annu Rev Chem Biomol Eng. 2018 Jun 7;9:105-127 [PMID: 29579402]
  386. Exp Biol Med (Maywood). 2016 May;241(9):919-29 [PMID: 27048557]
  387. Antiviral Res. 2017 Sep;145:54-59 [PMID: 28733113]
  388. ACS Med Chem Lett. 2013 Jan 29;4(2):302-5 [PMID: 24900663]
  389. Nature. 1995 Apr 6;374(6522):546-9 [PMID: 7700380]
  390. Oncoimmunology. 2015 Jan 9;4(4):e974411 [PMID: 26137405]
  391. J Leukoc Biol. 2011 Jun;89(6):945-53 [PMID: 21393420]

Grants

  1. DP2 TR002776/NCATS NIH HHS

MeSH Term

Animals
Biocompatible Materials
Cancer Vaccines
Humans
Immunotherapy
Lymph Nodes
Neoplasms
Precision Medicine

Chemicals

Biocompatible Materials
Cancer Vaccines
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0cancervaccinesdeliveryimmuneincludingtoxicityclinicaldesignefficacyvaccineBiomaterialsdevelopmenttherapeuticmeansgeneratereactivitytumorsexploredsinceearlydiscoverytumor-specificantigensGeorgKlein1960sHoweverchallengesweakimmunogenicitysystemicoff-targeteffectsremainbarriersbroadtranslationAdvancesimplementationbiomaterialsnowenablingenhancedreducedcontrollingpresentationreleasecomponentscellsmicroenvironmentdiscussrationalstatusseveralclassesDNAmRNApeptide/proteincell-basedalongnovelbiomaterial-basedtechnologiesimprovesafetystrategiesdesigningnewplatformspersonalizedalsoconsideredvaccine-basedimmunotherapyCancerImmunotherapyNanomedicineNucleicacidPersonalizedtherapyTargetedTranslationalresearch

Similar Articles

Cited By